Nuveen LLC Takes Position in Recursion Pharmaceuticals, Inc. $RXRX

Key Points

• Nuveen LLC has acquired 1,912,620 shares of Recursion Pharmaceuticals, valued at approximately $10.1 million, representing about 0.48% of the company.
• Analysts have given Recursion Pharmaceuticals a consensus rating of "Hold" with an average target price of $7.00, indicating mixed outlooks on the company's stock.
• Recursion Pharmaceuticals reported a 33.3% year-over-year revenue increase for the latest quarter, yet its earnings per share were below analysts' expectations.

Nuveen LLC acquired a new position in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Free Report) in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,912,620 shares of the company's stock, valued at approximately $10,118,000. Nuveen LLC owned approximately 0.48% of Recursion Pharmaceuticals as of its most recent SEC filing.

Other large investors also recently made changes to their positions in the company. ARK Investment Management LLC grew its holdings in Recursion Pharmaceuticals by 7.6% during the 1st quarter. ARK Investment Management LLC now owns 34,815,502 shares of the company's stock valued at $184,174,000 after purchasing an additional 2,469,104 shares in the last quarter. Softbank Group CORP. acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $99,152,000. Kinnevik AB publ grew its holdings in Recursion Pharmaceuticals by 12.8% during the 1st quarter. Kinnevik AB publ now owns 13,434,171 shares of the company's stock valued at $71,067,000 after purchasing an additional 1,528,503 shares in the last quarter. Novo Holdings A S acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $68,375,000. Finally, Laurion Capital Management LP acquired a new stake in Recursion Pharmaceuticals during the 4th quarter valued at $16,611,000. Institutional investors and hedge funds own 89.06% of the company's stock.

Insider Activity at Recursion Pharmaceuticals

In other news, insider Najat Khan sold 36,599 shares of Recursion Pharmaceuticals stock in a transaction dated Monday, August 18th. The shares were sold at an average price of $5.52, for a total value of $202,026.48. Following the completion of the transaction, the insider directly owned 668,197 shares of the company's stock, valued at approximately $3,688,447.44. The trade was a 5.19% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 8.43% of the company's stock.

Recursion Pharmaceuticals Stock Down 0.6%

NASDAQ RXRX traded down $0.03 during trading hours on Thursday, reaching $4.86. 12,684,277 shares of the company traded hands, compared to its average volume of 18,206,698. Recursion Pharmaceuticals, Inc. has a 12 month low of $3.79 and a 12 month high of $12.36. The company has a current ratio of 3.58, a quick ratio of 3.58 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $2.11 billion, a PE ratio of -2.73 and a beta of 0.93. The company has a 50 day moving average of $5.45 and a two-hundred day moving average of $5.69.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Tuesday, August 5th. The company reported ($0.41) EPS for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). Recursion Pharmaceuticals had a negative net margin of 1,004.91% and a negative return on equity of 76.09%. The company had revenue of $19.10 million for the quarter, compared to the consensus estimate of $15.38 million. During the same quarter last year, the company earned ($0.40) earnings per share. The company's revenue was up 33.3% compared to the same quarter last year. As a group, equities analysts expect that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.

Analyst Upgrades and Downgrades

A number of equities research analysts recently weighed in on the stock. Morgan Stanley assumed coverage on shares of Recursion Pharmaceuticals in a report on Thursday, July 3rd. They set an "equal weight" rating and a $5.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $8.00 price target on shares of Recursion Pharmaceuticals in a report on Tuesday, July 8th. Two investment analysts have rated the stock with a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Hold" and a consensus price target of $7.00.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.